Impossible Foods has filed a patent for materials and methods that involve overexpression of a transcriptional activator called retrograde regulation protein 1 (Rtg1) to increase the expression of one or more polypeptides. The patent claim describes a yeast cell comprising exogenous nucleic acids encoding Rtg and a polypeptide, operably linked to promoter elements. GlobalData’s report on Impossible Foods gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Impossible Foods, edible protein hydrolysis was a key innovation area identified from patents. Impossible Foods's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230193338A1) describes a yeast cell that has been genetically modified to express specific proteins. The yeast cell contains two exogenous nucleic acids, one encoding a retrograde regulation protein (Rtg) and the other encoding a polypeptide. The Rtg protein can be either Rtg1 or Rtg2 from Pichia pastoris or Saccharomyces cerevisiae. The polypeptide can be various types of proteins, including antibodies, enzymes, regulatory proteins, peptide hormones, blood clotting proteins, cytokines, cytokine inhibitors, and heme-binding proteins.
The yeast cell can have the exogenous nucleic acids stably integrated into its genome or expressed from a replication-competent plasmid. The nucleic acids are controlled by promoter elements, which can be constitutive or inducible. Inducible promoter elements, such as methanol-inducible promoter elements, can be used to regulate the expression of the proteins.
In addition to the Rtg and polypeptide encoding nucleic acids, the yeast cell can also contain a third exogenous nucleic acid encoding a transcriptional activator, such as Mxr1, Mit1, or Trm1. This transcriptional activator is operably linked to one of the promoter elements.
Furthermore, the yeast cell can be modified to express multiple transcriptional activators, each linked to a different promoter element. The yeast cell can also contain a fourth exogenous nucleic acid encoding heme biosynthesis enzymes, which are involved in the production of heme, an important molecule in various biological processes.
The patent also describes methods for expressing the polypeptides using the genetically modified yeast cells. The yeast cells are cultured under conditions suitable for the expression of the exogenous nucleic acids.
Overall, this patent presents a novel approach to genetically modifying yeast cells for the expression of specific proteins. The use of different promoter elements, transcriptional activators, and heme biosynthesis enzymes allows for precise control and optimization of protein expression in yeast cells. This technology has potential applications in various fields, including biotechnology, pharmaceuticals, and industrial processes.